Stockscreener 앱 받기
23.00
0.61%
0.14
시간 외 거래:
23.00
전일 마감가:
$22.86
열려 있는:
$23.07
하루 거래량:
259.30K
Relative Volume:
0.41
시가총액:
$1.69B
수익:
$81.26M
순이익/손실:
$-102.66M
주가수익비율:
-16.82
EPS:
-1.3678
순현금흐름:
$-77.62M
1주 성능:
-3.20%
1개월 성능:
-4.76%
6개월 성능:
-1.08%
1년 성능:
+72.54%
1일 변동 폭
$22.99
$23.59
1주일 범위
$22.72
$24.25
52주 변동 폭
$11.51
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
23.00 | 1.68B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView
Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
ZYME|Zymeworks Inc|Price:22.860|Chg%:-0.260 - TradingKey
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance
ETFs Investing in Zymeworks Inc. Stocks - TradingView
Hillsdale Investment Management Inc. Has $8.65 Million Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Pictet Asset Management Holding SA Has $232,000 Stock Position in Zymeworks Inc. $ZYME - MarketBeat
Theravance stock down 3% after Zymeworks announces buyout - MSN
Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - Ad-hoc-news.de
Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de
Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha
Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria
Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan
Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et
Enterprise value to EBIT forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - Ad-hoc-news.de
Zymeworks Inc. (ZYME): Exploring the Potential of an Undervalued Biotech in OncologyEarnings Stability Report - dars.gov.et
ZYME Q1 2026 Earnings: Wide EPS Miss Amid No Revenue as Operating Losses DeepenReturn On Assets - dars.gov.et
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView
The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - ad-hoc-news.de
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
Zymeworks to buy troubled U.S.-Irish pharma company Theravance for US$929M - The Logic
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Stifel reiterates Zymeworks stock Buy rating at $47 target By Investing.com - Investing.com South Africa
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com UK
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):